RWJBarnabas Health and Rutgers Cancer Institute to Present Practice-Changing Research at 2025 ASCO Annual Meeting | Newswise
Oral Abstract Session
Abstract No.
Title
Presentation Date/Time
Location
Abstract 12005
Results of a multisite randomized trial of Bright IDEAS-Young Adults: Efficacy of problem-solving skills training on distress and health-related quality of life.
Sunday, June 1, 2025, 9:45 a.m. CDT
S100bc
Abstract LBA5507
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).
Monday, June 2, 2025, 10:00 a.m. CDT
S100a
Abstract 501
Predicting pathologic complete response (pCR) from clinicopathologic variables and HER2DX genomic test in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): Secondary results from the EA1181/CompassHER2 pCR trial.
Monday, June 2, 2025, 3:00 p.m. CDT
Hall B1
Abstract 5007
A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.
Tuesday, June 3, 2025, 9:45 a.m. CDT
Hall D1
Poster Session
Abstract No.
Title
Presentation Date/Time
Location
Abstract 3575
Effect of race/ethnicity on clinical outcomes for metastatic colorectal cancer (mCRC) patients in phase 1 trials: A dual institution experience.
Saturday, May 31, 2025, 9:00 a.m. CDT
Hall A
Abstract TPS3633
A phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer: Big Ten Cancer Research Consortium GI22-588.
Saturday, May 31, 2025, 9:00 a.m. CDT
Hall A
Abstract TPS3643
Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
Saturday, May 31, 2025, 9:00 a.m. CDT
Hall A
Abstract 4124
Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter?
Saturday, May 31, 2025, 9:00 a.m. CDT
Hall A
Abstract 4166
The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC).
Saturday, May 31, 2025, 9:00 a.m. CDT
Hall A
Abstract 4200
Circulating tumor DNA-based genomic profiling and real-world outcomes in cancer of unknown primary (CUP).
Saturday, May 31, 2025, 9:00 a.m. CDT
Hall A
Abstract 10568
Discrepancies between germline and somatic laboratories in the reporting of germline cancer predisposition variants.
Saturday, May 31, 2025, 1:30 p.m. CDT
Hall A
Abstract 11038
Demographic and clinical factors associated with young-onset rectal cancer: Is the Latinx population at higher risk?
Saturday, May 31, 2025, 1:30 p.m. CDT
Hall A
Abstract 1525
From food deserts to clinical trial deserts: Challenges in access to breast cancer trials.
Sunday, June 1, 2025, 9:00 a.m. CDT
Hall A
Abstract 5563
Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti–immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830.
Sunday, June 1, 2025, 9:00 a.m. CDT
Hall A
Abstract 6538
Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?
Sunday, June 1, 2025, 9:00 a.m. CDT
Hall A
Abstract 7046
Safety and efficacy of AZD0486, a CD19xCD3 T-cell engager, in relapsed or refractory diffuse large B-cell lymphoma.
Sunday, June 1, 2025, 9:00 a.m. CDT
Hall A
Abstract 7063
Immune biomarkers as predictors of response to mosunetuzumab in previously untreated follicular (FL) and marginal zone lymphoma (MZL).
Sunday, June 1, 2025, 9:00 a.m. CDT
Hall A
Abstract TPS7083
SOUNDTRACK-E: A phase 1/2, open-label, multicenter study to evaluate the safety and efficacy of AZD0486 monotherapy or combination therapy in patients with mature B-cell malignancies.
Sunday, June 1, 2025, 9:00 a.m. CDT
Hall A
Abstract TPS7085
ALPHA3: A pivotal phase 2 study of first-line (1L) consolidation with cemacabtagene ansegedleucel (cema-cel) in patients (pts) with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy.
Sunday, June 1, 2025, 9:00 a.m. CDT
Hall A
Abstract TPS9596
A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma.
Sunday, June 1, 2025,
9:00 a.m. CDT
Hall A
Abstract 5067
Phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Monday, June 2, 2025, 9:00 a.m. CDT
Hall A
Abstract 524
Impact of initial chemotherapy dosing on subsequent dosing patterns and treatment completion in early-stage breast cancer.
Monday, June 2, 2025, 9:00 a.m. CDT
Hall A
Abstract 547
Obesity, chemotherapy dosing, and toxicity: Results from the Optimal Breast Cancer Chemotherapy Dosing study.
Monday, June 2, 2025, 9:00 a.m. CDT
Hall A
Abstract TPS1133
Adaptive designed eniluracil + capecitabine phase 2 trial in advanced or metastatic breast cancer patients.
Monday, June 2, 2025, 9:00 a.m. CDT
Hall A
Abstract 5089
Prognostic validation of six androgen production, uptake, and conversion genes (APUC-6) in the CHAARTED prostate cancer trial.
Monday, June 2, 2025, 9:00 a.m. CDT
Hall A
Abstract 2667
Vedolizumab or infliximab: Treatment option in immune checkpoint inhibitor–induced colitis.
Monday, June 2, 2025, 1:30 p.m. CDT
Hall A
Abstract 3124
Clinical performance of Signatera Genome assay in a cohort of patients (pts) with solid tumors.
Monday, June 2, 2025, 1:30 p.m. CDT
Hall A
Abstract 3154
Effect of biopsy requirement on patient enrollment to phase I trials in cancer.
Monday, June 2, 2025, 1:30 p.m. CDT
Hall A
Abstract 3087
A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
Monday, June 2, 2025, 1:30 p.m. CDT
Hall A
Publication Only
Session title
Presentation title
Presentation Date/Time
Location
Abstract e13567
The use of peripheral intravenous catheters (PIV) for lymphoma patients receiving anthracycline-based chemotherapy: A multicenter real-world analysis (RWA).
N/A
N/A
Abstract e13741
Evaluating uptake of targeted agents by race/ethnicity in patients receiving first-line treatment for chronic lymphocytic leukemia (CLL).
N/A
N/A
Abstract e15152
Safety and efficacy of eniluracil + capecitabine (6422 + Cap) in phase 1b trial.
N/A
N/A
Abstract e15605
Actionability landscape and biomarker utility in a colorectal cancer alliance cohort: Initial results from the Know Your Biomarker program.
N/A
N/A
Abstract e15674
Racial disparities and prognostic factors in cancer-specific survival for patients with metastatic rectal cancer.
N/A
N/A
Abstract e15704
Risk factors and outcomes of second primary cancers in colorectal cancer patients by primary tumor site.
N/A
N/A
Abstract e15707
Trends in second primary cancer incidence by primary colorectal cancer location.
N/A
N/A
Abstract e15711
Evaluating the immune landscape in early onset colorectal cancer patients.
N/A
N/A
Abstract e16181
Recurrence-free survival dynamics following adjuvant chemotherapy for resected non-colorectal cancers of the gastrointestinal tract: A systematic review of randomized controlled trials.
N/A
N/A
Abstract e17044
Abiraterone with discontinuation of gonadotropin-releasing hormone (GnRH) analogues in patients (pts) with metastatic prostate cancer (PC): Survival results from a single-arm, phase II study.
N/A
N/A
Abstract e19505
Bispecific antibody therapy in central nervous system (CNS) multiple myeloma (MM): Multicenter retrospective study.
N/A
N/A
Abstract e19537
Exploring steroid prophylaxis to mitigate CRS: Enhancing access to bispecific antibodies in RRMM.
shareShare
N/A
N/A
Abstract e20676
Genetic characteristics and clinical outcomes of driver mutant oligometastatic non small cell lung cancer treated with combination definitive chemoradiotherapy and targeted systemic therapy.
N/A
N/A
Abstract e21510
Epidemiologic factors and survival outcomes of patients with metastatic malignant melanoma.
N/A
N/A
Abstract e23098
Time toxicity of intravesical sequential gemcitabine and docetaxel.
N/A
N/A
Abstract e24007
Incidence and survival rates of patients with primary malignant cardiac tumors: A SEER based study.
N/A
N/A
